These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20130861)

  • 1. The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting.
    Sui H; Bai Y; Wang K; Li X; Song C; Fu F; Zhang Y; Li L
    Cancer Immunol Immunother; 2010 Jul; 59(7):989-99. PubMed ID: 20130861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting].
    Wang K; Sui H; Li L; Li X; Wang L
    Zhongguo Fei Ai Za Zhi; 2010 Aug; 13(8):773-6. PubMed ID: 20704816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination.
    Ni J; Schirrmacher V; Fournier P
    Vaccine; 2010 Oct; 28(42):6891-900. PubMed ID: 20709006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo.
    He D; Sun L; Li C; Hu N; Sheng Y; Chen Z; Li X; Chi B; Jin N
    Viruses; 2014 Feb; 6(2):856-74. PubMed ID: 24553109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumor research on mouse melanoma with combined application of Newcastle disease virus and its HN gene].
    Mi ZQ; Jin NY; Sun YC; Li X; Lian H; Li J; Guan GF
    Ai Zheng; 2004 Aug; 23(8):910-3. PubMed ID: 15301713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
    Schirrmacher V; Haas C; Bonifer R; Ertel C
    Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes.
    Firouzamandi M; Moeini H; Hosseini D; Bejo MH; Omar AR; Mehrbod P; Ideris A
    J Vet Sci; 2016 Mar; 17(1):21-6. PubMed ID: 27051336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy.
    He J; Pan Z; Tian G; Liu X; Liu Y; Guo X; An Y; Song L; Wu H; Cao H; Yu D; Che R; Xu P; Rasoul LM; Li D; Yin J
    Virus Res; 2016 Aug; 221():23-9. PubMed ID: 27164362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus.
    Fournier P; Zeng J; Von Der Lieth CW; Washburn B; Ahlert T; Schirrmacher V
    Int J Oncol; 2004 Mar; 24(3):623-34. PubMed ID: 14767547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved protection from velogenic Newcastle disease virus challenge following multiple immunizations with plasmid DNA encoding for F and HN genes.
    Loke CF; Omar AR; Raha AR; Yusoff K
    Vet Immunol Immunopathol; 2005 Jul; 106(3-4):259-67. PubMed ID: 15963824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity.
    Ni J; Galani IE; Cerwenka A; Schirrmacher V; Fournier P
    Vaccine; 2011 Feb; 29(6):1185-93. PubMed ID: 21172381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a potential neutralizing linear epitope of hemagglutinin-neuraminidase in Newcastle disease virus.
    Jin Z; Wei Q; Bi Y; Li Y; Huo N; Mou S; Wang W; Liu H; Yang Z; Chen H; Xiao S
    Virol J; 2021 Jan; 18(1):8. PubMed ID: 33407693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Induction of apoptosis in human hepatoma cell line SMMC7721 by Newcastle disease virus HN gene].
    Sun YC; Jin NY; Mi ZQ; Li X; Lian H; Li P
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):279-82. PubMed ID: 15996319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
    Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
    Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals.
    Peeters BP; de Leeuw OS; Verstegen I; Koch G; Gielkens AL
    Vaccine; 2001 Feb; 19(13-14):1616-27. PubMed ID: 11166884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avian adeno-associated virus-based expression of Newcastle disease virus hemagglutinin-neuraminidase protein for poultry vaccination.
    Perozo F; Villegas P; Estevez C; Alvarado IR; Purvis LB; Saume E
    Avian Dis; 2008 Jun; 52(2):253-9. PubMed ID: 18646454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and in vitro characterization of a bivalent DNA containing HN and F genes of velogenic Newcastle disease virus.
    Chaturvedi U; Kalim S; Desai G; Ratta B; Kumar R; Ravindra PV; Kumar S; Dash BB; Tiwari S; Sahoo AP; Tiwari AK
    Indian J Exp Biol; 2011 Feb; 49(2):140-5. PubMed ID: 21428216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newcastle disease virus (NDV) vaccine based on immunization with avian cells expressing the NDV hemagglutinin-neuraminidase glycoprotein.
    Cosset FL; Bouquet JF; Drynda A; Chebloune Y; Rey-Senelonge A; Kohen G; Nigon VM; Desmettre P; Verdier G
    Virology; 1991 Dec; 185(2):862-6. PubMed ID: 1660204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
    Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
    Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.